نتایج جستجو برای: hemophilia

تعداد نتایج: 6367  

2009

6.5 Range of Application, Dosage, Mode of Administration 6.5.1 General Information 6.5.2 Indications for Replacement Therapy Using Factor Concentrates 6.5.3 Dosage, Mode of Administration 6.5.3.1 Replacement in Children with Hemophilia A, B or von Willebrand Syndrome 6.5.3.2 Replacement in Adults with Hemophilia A, B or von Willebrand Syndrome 6.5.3.3 Indications and Recommended Doses for Treat...

Journal: :Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2015
C X Chen M M Ullman J D Hord R Kulkarni B A Konkle J R Baker B Riske M Koerper M Lou J Wu M B Nichol

 Of those included, 47.2% were adults, 69.3% had HA and 61.5% had severe hemophilia (HA N=151, HB N=47). Significantly fewer individuals on prophylaxis vs. on-demand treatment were adults, had HB or had mild/moderate hemophilia. (Table 1)  An ABR of 1-10 was recorded in 58% of participants. A higher percentage of adults vs. children with severe hemophilia had ABR ≥11 among those treating on-d...

2016
Sarah Bérubé Florine Mouillard Claudine Amesse Serge Sultan

BACKGROUND In pediatric hemophilia, caregivers are facing unique challenges to adherence and self-care in children and adolescents with hemophilia. Hemophilia treatment requires adequate prophylaxis and on-demand treatment, as well as a clear behavioral strategy to limit risk-taking in terms of physical exercise and diet. Medication adherence rates of hemophilia patients have been reported to d...

2016
Chien-Min Chen Yao-Hsu Yang Chia-Hao Chang Chih-Cheng Chen Pau-Chung Chen

INTRODUCTION Rehabilitation plays an important role in the physical health of patients with hemophilia. However, comprehensive information regarding the utilization of rehabilitation for such patients remains scarce. AIM This population-based study aimed to examine the characteristics, trends, and most important factors affecting rehabilitation usage in patients with hemophilia A using a nati...

Journal: :Bosnian journal of basic medical sciences 2009
Bukurije Zhubi Ymer Mekaj Zana Baruti Ilirijane Bunjaku Mazllum Belegu

One of the largest therapeutic problem during the continuous treatment of the patients with Hemophilia A and B, are viral infections as Hepatitis B and C, and HIV, and the other infective diseases, which can be transmitted by the transfusion of blood products. The aim of this study is to analyze the complications of the hemophiliacs in Kosovo which have been treated with fresh frozen plasma, cr...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2009
Dan Xu Zaida Alipio Louis M Fink Dorothy M Adcock Jianchang Yang David C Ward Yupo Ma

Hemophilia A is caused by mutations within the Factor VIII (FVIII) gene that lead to depleted protein production and inefficient blood clotting. Several attempts at gene therapy have failed for various reasons-including immune rejection. The recent generation of induced pluripotent stem (iPS) cells from somatic cells by the ectopic expression of 3 transcription factors, Oct4, Sox2, and Klf4, pr...

Journal: :Blood 2011
Henrik Østergaard Jais R Bjelke Lene Hansen Lars Christian Petersen Anette A Pedersen Torben Elm Flemming Møller Mette B Hermit Pernille K Holm Thomas N Krogh Jørn M Petersen Mirella Ezban Brit B Sørensen Mette D Andersen Henrik Agersø Haleh Ahmadian Kristoffer W Balling Marie Louise S Christiansen Karin Knobe Timothy C Nichols Søren E Bjørn Mikael Tranholm

Current management of hemophilia B entails multiple weekly infusions of factor IX (FIX) to prevent bleeding episodes. In an attempt to make a longer acting recombinant FIX (rFIX), we have explored a new releasable protraction concept using the native N-glycans in the activation peptide as sites for attachment of polyethylene glycol (PEG). Release of the activation peptide by physiologic activat...

Journal: :Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2009

6.5 Range of Application, Dosage, Mode of Administration 6.5.1 General Information 6.5.2 Indications for Replacement Therapy Using Factor Concentrates 6.5.3 Dosage, Mode of Administration 6.5.3.1 Replacement in Children with Hemophilia A, B or von Willebrand Syndrome 6.5.3.2 Replacement in Adults with Hemophilia A, B or von Willebrand Syndrome 6.5.3.3 Indications and Recommended Doses for Treat...

ژورنال: مجله دندانپزشکی 2020

Background and Aims: The chronic blood disorders could have negative effects on various fields of patient’s quality of life. The aim of this study was to evaluate the relationship between the quality of life and oral health in major thalassemia and hemophilia patients. Materials and Methods: This cross- sectional study was performed in 1398 on 56 hemophilia patients and 35 thalassemia major pa...

Journal: :مجله دانشگاه علوم پزشکی کرمانشاه 0
farzad company dept. of haematology & oncology, school of medicine, kurdistan university of medical science. sanandaj nazila rezaei dept. of haematology & oncology, school of medicine, kurdistan university of medical science. sanandaj mariam aliasgharpoor dept. of haematology & oncology, school of medicine, kurdistan university of medical science. sanandaj

background: factor viii inhibitor is one of the most problems in the treatment of hemophilia. patients with hemophilia who have inhibitors are capable of severe hemorrhage and treatments of these patients are more expensive and more difficult than those patients without inhibitor. the aim of present study was to determine the prevalence of inhibitor and to assess the necessity of screening of t...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید